Skip to content
2000
Volume 25, Issue 2
  • ISSN: 1871-529X
  • E-ISSN: 2212-4063

Abstract

The past decade has appreciated personalized medicine as a novel medical approach that deals with all practices that are tailored to individual patients. Personalized treatment or personalized cardiology for cardiovascular disorders is an emerging medicine system for related patients. Personalized cardiology is solely based on genomics and proteomics; molecular diagnostics and biomarkers of the cardiovascular system link diagnosis with therapy. Bioinformatics is useful in CVD risk stratification and might improve risk-estimating algorithms. Personalized cardiology involves 3D printing, pharmacotherapy, surgery, lifestyle modifications, and combinations thereof. Understanding the pathology of CVD and identifying causative factors at the individual level can provide opportunities for developing personalized medicine. Since it offers novel avenues for diagnosing, preventing, and treating CVD, molecular genetics has made a substantial contribution to the field of molecular cardiology. Nonetheless, there are still a lot of obstacles to overcome from the standpoints of science and policy. These obstacles can be avoided using evidence-based procedures, clinical applications, biomarker-based detection techniques, comprehensive concepts, and understanding. Targeted therapies may be developed as a result of improved disease classification and a better knowledge of the individual differences in pathology. Cardiovascular disorders, like hypertension, angina, or ischemic heart, a condition of reduced blood flow to the heart, coronary artery disease or damaged blood vessels, myocardial infarction or resisted blood flow to the myocardium, and cardiac arrhythmia or irregular cardiac cycles are the primary targets for personalized cardiology. The current review discusses various parameters for personalizing the treatment of cardiovascular disorders.

© 2025 Bentham Science Publishers
Loading

Article metrics loading...

/content/journals/chddt/10.2174/011871529X361429250215190129
2025-02-25
2025-10-08

  • From This Site

    /content/journals/chddt/10.2174/011871529X361429250215190129
    dcterms_title,dcterms_subject,pub_keyword
    -contentType:Contributor -contentType:Concept -contentType:Institution
    10
    5
Loading full text...

Full text loading...

References

  1. The shift from personalized medicine to precision medicine and precision public health.2016Available from: https://blogs.cdc.gov/genomics/2016/04/21/shift/
  2. Genetics2024Available from: https://medlineplus.gov/ency/article/002048.htm
  3. Di SanzoM. CipolloniL. BorroM. La RussaR. SanturroA. ScopettiM. SimmacoM. FratiP. Clinical applications of personalized medicine: A new paradigm and challenge.Curr. Pharm. Biotechnol.201718319420310.2174/138920101866617022410560028240172
     [Google Scholar]
  4. VogenbergF.R. Isaacson BarashC. PurselM. Personalized medicine: Part 1: Evolution and development into theranostics.P&T2010351056057621037908
     [Google Scholar]
  5. VogenbergF.R. BarashC.I. PurselM. Personalized medicine: part 2: Ethical, legal, and regulatory issues.P&T2010351162464221139819
     [Google Scholar]
  6. JakkaS. RossbachM. An economic perspective on personalized medicine.HUGO J.2013711610.1186/1877‑6566‑7‑1
     [Google Scholar]
  7. SadéeW. DaiZ. Pharmacogenetics/genomics and personalized medicine.Hum. Mol. Genet.200514Suppl. 2R207R21410.1093/hmg/ddi26116244319
     [Google Scholar]
  8. AbrahamsE. GinsburgG.S. SilverM. The personalized medicine coalition.Am. J. Pharmacogenomics20055634535510.2165/00129785‑200505060‑0000216336000
     [Google Scholar]
  9. VuT. ClaretF.X. Trastuzumab: Updated mechanisms of action and resistance in breast cancer.Front. Oncol.201226210.3389/fonc.2012.0006222720269
     [Google Scholar]
  10. MathurS. SuttonJ. Personalized medicine could transform healthcare.Biomed. Rep.2017713510.3892/br.2017.92228685051
     [Google Scholar]
  11. MaliP. EsveltK.M. ChurchG.M. Cas9 as a versatile tool for engineering biology.Nat. Methods2013101095796310.1038/nmeth.264924076990
     [Google Scholar]
  12. MiedanyY.E. MABS: Targeted therapy tailored to the patient’s need.Br. J. Nurs.201524Sup16aSuppl. 1S4S1310.12968/bjon.2015.24.Sup16a.S426946646
     [Google Scholar]
  13. FlorenceA.T. LeeV.H.L. Personalised medicines: More tailored drugs, more tailored delivery.Int. J. Pharm.20114151-2293310.1016/j.ijpharm.2011.04.04721565262
     [Google Scholar]
  14. JainKK Textbook of Personalized Medicine.Springer
     [Google Scholar]
  15. JainK.K. PharmabiotechJ. Personalized management of cardiovascular disorders.Med. Princ. Pract.201726539941410.1159/00048140328898880
     [Google Scholar]
  16. ShapiroS.D. Merging personalized medicine and biology of aging in chronic obstructive pulmonary disease.Am. J. Respir. Crit. Care Med.2011184886486610.1164/rccm.201108‑1486ED22003144
     [Google Scholar]
  17. Piquette-MillerM. GrantD.M. The art and science of personalized medicine.Clin. Pharmacol. Ther.200781331131510.1038/sj.clpt.610013017339856
     [Google Scholar]
  18. LunshofJ.E. PirmohamedM. GurwitzD. Personalized medicine: Decades away?Pharmacogenomics20067223724110.2217/14622416.7.2.23716515403
     [Google Scholar]
  19. BelmontJW HardenbolP WillisTD YuF YangH The International HapMap projectNature2003426696878979610.1038/nature02168
     [Google Scholar]
  20. GuttmacherA.E. CollinsF.S. Genomic medicine--A primer.N. Engl. J. Med.2002347191512152010.1056/NEJMra01224012421895
     [Google Scholar]
  21. ManaceL.C. GodiwalaT.N. BabyatskyM.W. Genomics of cardiovascular disease.Mt. Sinai J. Med.200976661362310.1002/msj.2015120014425
     [Google Scholar]
  22. LeeM.S. FlammerA.J. LermanL.O. LermanA. Personalized medicine in cardiovascular diseases.Korean Circ. J.201242958359110.4070/kcj.2012.42.9.58323091501
     [Google Scholar]
  23. BonterK. DesjardinsC. CurrierN. PunJ. AshburyF.D. Personalised medicine in Canada: A survey of adoption and practice in oncology, cardiology and family medicine.BMJ Open201111e00011010.1136/bmjopen‑2011‑00011022021765
     [Google Scholar]
  24. ZinehI. PebancoG.D. AquilanteC.L. GerhardT. BeitelsheesA.L. BeasleyB.N. HartzemaA.G. Discordance between availability of pharmacogenetics studies and pharmacogenetics-based prescribing information for the top 200 drugs.Ann. Pharmacother.200640463964410.1345/aph.1G46416595569
     [Google Scholar]
  25. GinsburgG. McCarthyJ.J. Personalized medicine: Revolutionizing drug discovery and patient care.Trends Biotechnol.2001191249149610.1016/S0167‑7799(01)01814‑511711191
     [Google Scholar]
  26. TracyT. WuL. LiuX. ChengS. LiX. 3D printing: Innovative solutions for patients and pharmaceutical industry.Int. J. Pharm.202363112248010.1016/j.ijpharm.2022.12248036509225
     [Google Scholar]
  27. Spritam (levetiracetam) FDA Approval History.2023Available from: https://www.drugs.com/history/spritam.html#:~:text=Spritam%20FDA%20Approval%20History&text=Levetiracetam%20was%20first%20approved%20under,with%20a%20sip%20of%20liquid.
  28. SandanamsamyL. HarunW.S.W. IshakI. RomlayF.R.M. KadirgamaK. RamasamyD. IdrisS.R.A. TsumoriF. A comprehensive review on fused deposition modelling of polylactic acid.Prog Addit Manuf20238577579910.1007/s40964‑022‑00356‑w38625345
     [Google Scholar]
  29. Seoane-ViañoI. JanuskaiteP. Alvarez-LorenzoC. BasitA.W. GoyanesA. Semi-solid extrusion 3D printing in drug delivery and biomedicine: Personalised solutions for healthcare challenges.J. Control. Release202133236738910.1016/j.jconrel.2021.02.02733652114
     [Google Scholar]
  30. BandariS. NyavanandiD. DumpaN. RepkaM.A. Coupling hot melt extrusion and fused deposition modeling: Critical properties for successful performance.Adv. Drug Deliv. Rev.2021172526310.1016/j.addr.2021.02.00633571550
     [Google Scholar]
  31. ChenX WangS WuJ DuanS WangX HongX The application and challenge of Binder Jet 3D printing technology in pharmaceutical manufacturing.Pharmaceutics20221412258910.3390/pharmaceutics14122589
     [Google Scholar]
  32. AwadA. FinaF. GoyanesA. GaisfordS. BasitA.W. Advances in powder bed fusion 3D printing in drug delivery and healthcare.Adv. Drug Deliv. Rev.202117440642410.1016/j.addr.2021.04.02533951489
     [Google Scholar]
  33. MukhtarkhanovM PerveenA TalamonaD. Application of stereolithography based 3D printing technology in investment casting.Micromachines2020111094610.3390/mi11100946
     [Google Scholar]
  34. Mancilla-De-la-CruzJ. Rodriguez-SalvadorM. AnJ. ChuaC.K. Three-dimensional printing technologies for drug delivery applications: Processes, materials, and effects.IJB20228462210.18063/ijb.v8i4.62236404786
     [Google Scholar]
  35. KhaledS.A. BurleyJ.C. AlexanderM.R. YangJ. RobertsC.J. 3D printing of five-in-one dose combination polypill with defined immediate and sustained release profiles.J. Control. Release201521730831410.1016/j.jconrel.2015.09.02826390808
     [Google Scholar]
  36. LafeberM. GrobbeeD.E. BotsM.L. ThomS. WebsterR. RodgersA. VisserenF.L.J. SpieringW. The evening versus morning polypill utilization study: The TEMPUS rationale and design.Eur. J. Prev. Cardiol.201421442543310.1177/204748731347696123382539
     [Google Scholar]
  37. CareyK.M. CorneeM.R. DonovanJ.L. KanaanA.O. A polypill for all? Critical review of the polypill literature for primary prevention of cardiovascular disease and stroke.Ann. Pharmacother.201246568869510.1345/aph.1Q62122570437
     [Google Scholar]
  38. Hippisley-CoxJ. CouplandC. Effect of combinations of drugs on all cause mortality in patients with ischaemic heart disease: Nested case-control analysis.BMJ200533074991059106310.1136/bmj.330.7499.105915879390
     [Google Scholar]
  39. YusufS. PaisP. AfzalR. XavierD. TeoK. EikelboomJ. SigamaniA. MohanV. GuptaR. ThomasN. Effects of a polypill (Polycap) on risk factors in middle-aged individuals without cardiovascular disease (TIPS): A phase II, double-blind, randomised trial.Lancet200937396721341135110.1016/S0140‑6736(09)60611‑519339045
     [Google Scholar]
  40. Polycap capsule: View uses, side effects, price and substitutes 2023Available from: https://www.1mg.com/drugs/polycap-capsule-165295#:~:text=Polycap%20Capsule%20is%20used%20for,It%20may%20cause%20dizziness.
  41. SchneebergerA. 3D screen printing enables application of integrated QR codes on pharmaceutical dosage forms in mass production – A game changer.Biomed. J. Sci. Tech. Res.202241410.26717/BJSTR.2022.41.006630
     [Google Scholar]
  42. KaravasiliC. ZgouroP. ManousiN. LazaridouA. ZacharisC.K. BouropoulosN. MoschakisT. FatourosD.G. Cereal-based 3D printed dosage forms for drug administration during breakfast in pediatric patients within a hospital setting.J. Pharm. Sci.202211192562257010.1016/j.xphs.2022.04.01335469835
     [Google Scholar]
  43. Polak-IwaniukA. Harasim-SymborE. GołaszewskaK. ChabowskiA. How hypertension affects heart metabolism.Front. Physiol.20191043510.3389/fphys.2019.0043531040794
     [Google Scholar]
  44. TsibulnikovS.Y. MaslovL.N. GorbunovA.S. VoronkovN.S. BoshchenkoA.A. PopovS.V. ProkudinaE.S. SinghN. DowneyJ.M. A review of humoral factors in remote preconditioning of the heart.J. Cardiovasc. Pharmacol. Ther.201924540342110.1177/107424841984163231035796
     [Google Scholar]
  45. Structure of the Heart.2023Available from: https://training.seer.cancer.gov/anatomy/cardiovascular/heart/structure.html#:~:text=The%20human%20heart%20is%20a,layers%20of%20a%20serous%20membrane
  46. MollovaM. BersellK. WalshS. SavlaJ. DasL.T. ParkS.Y. SilbersteinL.E. dos RemediosC.G. GrahamD. ColanS. KühnB. Cardiomyocyte proliferation contributes to heart growth in young humans.Proc. Natl. Acad. Sci. USA201311041446145110.1073/pnas.121460811023302686
     [Google Scholar]
  47. GruzdevaO.V. BorodkinaD.A. BelikE.V. AkbashevaO.E. PalichevaE.I. BarbarashO.L. Ghrelin physiology and pathophysiology: Focus on the cardiovascular system.Kardiologiia2019593606710.18087/cardio.2019.3.1022030990143
     [Google Scholar]
  48. SeoD.Y. KwakH.B. KimA.H. ParkS.H. HeoJ.W. KimH.K. KoJ.R. LeeS.J. BangH.S. SimJ.W. KimM. HanJ. Cardiac adaptation to exercise training in health and disease.Pflugers Arch.2020472215516810.1007/s00424‑019‑02266‑331016384
     [Google Scholar]
  49. ParkS. NguyenN.B. PezhoumanA. ArdehaliR. Cardiac fibrosis: Potential therapeutic targets.Transl. Res.201920912113710.1016/j.trsl.2019.03.00130930180
     [Google Scholar]
  50. SaxtonA. ChaudhryR. MannaB. Anatomy, Thorax, Heart Right Coronary Arteries.StatPearls2023
     [Google Scholar]
  51. HussainA. BurnsB. Anatomy, Thorax, Wall.StatPearls2023
     [Google Scholar]
  52. BuckbergG.D. NandaN.C. NguyenC. KocicaM.J. What is the heart? anatomy, function, pathophysiology, and misconceptions.J. Cardiovasc. Dev. Dis.2018523310.3390/jcdd502003329867011
     [Google Scholar]
  53. FedeleL. BrandT. The intrinsic cardiac nervous system and its role in cardiac pacemaking and conduction.J. Cardiovasc. Dev. Dis.2020745410.3390/jcdd704005433255284
     [Google Scholar]
  54. BhattacharyyaS. MunshiN.V. Development of the cardiac conduction system.Cold Spring Harb. Perspect. Biol.20201212a03740810.1101/cshperspect.a03740831988140
     [Google Scholar]
  55. ChanI.S. GinsburgG.S. Personalized medicine: Progress and promise.Annu. Rev. Genomics Hum. Genet.201112121724410.1146/annurev‑genom‑082410‑10144621721939
     [Google Scholar]
  56. ThomasM. LiebermanJ. LalA. Desperately seeking microRNA targets.Nat. Struct. Mol. Biol.201017101169117410.1038/nsmb.192120924405
     [Google Scholar]
  57. RodenD.M. AltmanR.B. BenowitzN.L. FlockhartD.A. GiacominiK.M. JohnsonJ.A. KraussR.M. McLeodH.L. RatainM.J. RellingM.V. RingH.Z. ShuldinerA.R. WeinshilboumR.M. WeissS.T. Pharmacogenomics: Challenges and opportunities.Ann. Intern. Med.20061451074975710.7326/0003‑4819‑145‑10‑200611210‑0000717116919
     [Google Scholar]
  58. AzizanE.A.B. PoulsenH. TulucP. ZhouJ. ClausenM.V. LiebA. ManieroC. GargS. BochukovaE.G. ZhaoW. ShaikhL.H. BrightonC.A. TeoA.E.D. DavenportA.P. DekkersT. TopsB. KüstersB. CeralJ. YeoG.S.H. NeogiS.G. McFarlaneI. RosenfeldN. MarassF. HadfieldJ. MargasW. ChaggarK. SolarM. DeinumJ. DolphinA.C. FarooqiI.S. StriessnigJ. NissenP. BrownM.J. Somatic mutations in ATP1A1 and CACNA1D underlie a common subtype of adrenal hypertension.Nat. Genet.20134591055106010.1038/ng.271623913004
     [Google Scholar]
  59. JørgensenA.B. Frikke-SchmidtR. NordestgaardB.G. Tybjærg-HansenA. Loss-of-function mutations in APOC3 and risk of ischemic vascular disease.N. Engl. J. Med.20143711324110.1056/NEJMoa130802724941082
     [Google Scholar]
  60. CrosbyJ. PelosoG.M. AuerP.L. CrosslinD.R. StitzielN.O. LangeL.A. LuY. TangZ.Z. ZhangH. HindyG. MascaN. StirrupsK. KanoniS. DoR. JunG. HuY. KangH.M. XueC. GoelA. FarrallM. DugaS. MerliniP.A. AsseltaR. GirelliD. OlivieriO. MartinelliN. YinW. ReillyD. SpeliotesE. FoxC.S. HveemK. HolmenO.L. NikpayM. FarlowD.N. AssimesT.L. FranceschiniN. RobinsonJ. NorthK.E. MartinL.W. DePristoM. GuptaN. EscherS.A. JanssonJ.H. Van ZuydamN. PalmerC.N. WarehamN. KochW. MeitingerT. PetersA. LiebW. ErbelR. KonigI.R. KruppaJ. DegenhardtF. GottesmanO. BottingerE.P. O’DonnellC.J. PsatyB.M. BallantyneC.M. AbecasisG. OrdovasJ.M. MelanderO. WatkinsH. Orho-MelanderM. ArdissinoD. LoosR.J. McPhersonR. WillerC.J. ErdmannJ. HallA.S. SamaniN.J. DeloukasP. SchunkertH. WilsonJ.G. KooperbergC. RichS.S. TracyR.P. LinD.Y. AltshulerD. GabrielS. NickersonD.A. JarvikG.P. CupplesL.A. ReinerA.P. BoerwinkleE. KathiresanS. Loss-of-function mutations in APOC3, triglycerides, and coronary disease.N. Engl. J. Med.20143711223110.1056/NEJMoa130709524941081
     [Google Scholar]
  61. WildeA.A.M. BezzinaC.R. Genetics of cardiac arrhythmias.Heart200591101352135810.1136/hrt.2004.04633416162633
     [Google Scholar]
  62. RodenD.M. BalserJ.R. GeorgeA.L.Jr AndersonM.E. Cardiac ion channels.Annu. Rev. Physiol.200264143147510.1146/annurev.physiol.64.083101.14510511826275
     [Google Scholar]
  63. ClancyC.E. KassR.S. Inherited and acquired vulnerability to ventricular arrhythmias: cardiac Na+ and K+ channels.Physiol. Rev.2005851334710.1152/physrev.00005.200415618477
     [Google Scholar]
  64. MohlerP.J. SchottJ.J. GramoliniA.O. DillyK.W. GuatimosimS. duBellW.H. SongL.S. HaurognéK. KyndtF. AliM.E. RogersT.B. LedererW.J. EscandeD. MarecH.L. BennettV. Ankyrin-B mutation causes type 4 long-QT cardiac arrhythmia and sudden cardiac death.Nature2003421692363463910.1038/nature0133512571597
     [Google Scholar]
  65. PlasterN.M. TawilR. Tristani-FirouziM. CanúnS. BendahhouS. TsunodaA. DonaldsonM.R. IannacconeS.T. BruntE. BarohnR. ClarkJ. DeymeerF. GeorgeA.L.Jr FishF.A. HahnA. NituA. OzdemirC. SerdarogluP. SubramonyS.H. WolfeG. FuY.H. PtáčekL.J. Mutations in Kir2.1 cause the developmental and episodic electrical phenotypes of Andersen’s syndrome.Cell2001105451151910.1016/S0092‑8674(01)00342‑711371347
     [Google Scholar]
  66. SplawskiI. TimothyK.W. SharpeL.M. DecherN. KumarP. BloiseR. NapolitanoC. SchwartzP.J. JosephR.M. CondourisK. Tager-FlusbergH. PrioriS.G. SanguinettiM.C. KeatingM.T. Ca(V)1.2 calcium channel dysfunction causes a multisystem disorder including arrhythmia and autism.Cell20041191193110.1016/j.cell.2004.09.01115454078
     [Google Scholar]
  67. OlsonT.M. MichelsV.V. BallewJ.D. ReynaS.P. KarstM.L. HerronK.J. HortonS.C. RodehefferR.J. AndersonJ.L. Sodium channel mutations and susceptibility to heart failure and atrial fibrillation.JAMA2005293444745410.1001/jama.293.4.44715671429
     [Google Scholar]
  68. BezzinaC. VeldkampM.W. van den BergM.P. PostmaA.V. RookM.B. ViersmaJ.W. van LangenI.M. Tan-SindhunataG. Bink-BoelkensM.T.E. van der HoutA.H. MannensM.M.A.M. WildeA.A.M. A single Na(+) channel mutation causing both long-QT and Brugada syndromes.Circ. Res.199985121206121310.1161/01.RES.85.12.120610590249
     [Google Scholar]
  69. GorącyJ. GorącyI. KaczmarczykM. ParczewskiM. CyryłowskiL. BrykczyńskiM. Peregud-PogorzelskaM. CiechanowiczA. VAMP-8 gene variant is associated with increased risk of early myocardial infarction.Arch. Med. Sci.20113344044310.5114/aoms.2011.2340922295026
     [Google Scholar]
  70. ShiffmanD. RowlandC.M. LouieJ.Z. LukeM.M. BareL.A. BolonickJ.I. YoungB.A. CataneseJ.J. StigginsC.F. PullingerC.R. TopolE.J. MalloyM.J. KaneJ.P. EllisS.G. DevlinJ.J. Gene variants of VAMP8 and HNRPUL1 are associated with early-onset myocardial infarction.Arterioscler. Thromb. Vasc. Biol.20062671613161810.1161/01.ATV.0000226543.77214.e416690874
     [Google Scholar]
  71. DaiX. WiernekS. EvansJ.P. RungeM.S. Genetics of coronary artery disease and myocardial infarction.World J. Cardiol.20168112310.4330/wjc.v8.i1.126839654
     [Google Scholar]
  72. ManolioT.A. BoerwinkleE. O’DonnellC.J. WilsonA.F. Genetics of ultrasonographic carotid atherosclerosis.Arterioscler. Thromb. Vasc. Biol.20042491567157710.1161/01.ATV.0000138789.11433.c115256397
     [Google Scholar]
  73. MacArthurJ. BowlerE. CerezoM. GilL. HallP. HastingsE. JunkinsH. McMahonA. MilanoA. MoralesJ. PendlingtonZ.M. WelterD. BurdettT. HindorffL. FlicekP. CunninghamF. ParkinsonH. The new NHGRI-EBI Catalog of published genome-wide association studies (GWAS Catalog).Nucleic Acids Res.201745D1D896D90110.1093/nar/gkw113327899670
     [Google Scholar]
  74. KathiresanS. MelanderO. AnevskiD. GuiducciC. BurttN.P. RoosC. HirschhornJ.N. BerglundG. HedbladB. GroopL. AltshulerD.M. Newton-ChehC. Orho-MelanderM. Polymorphisms associated with cholesterol and risk of cardiovascular events.N. Engl. J. Med.2008358121240124910.1056/NEJMoa070672818354102
     [Google Scholar]
  75. TeekakirikulP. KellyM.A. RehmH.L. LakdawalaN.K. FunkeB.H. Inherited Cardiomyopathies.J. Mol. Diagn.201315215817010.1016/j.jmoldx.2012.09.00223274168
     [Google Scholar]
  76. D’ArgenioV. FrissoG. PreconeV. BocciaA. FiengaA. PacileoG. LimongelliG. PaolellaG. CalabròR. SalvatoreF. DNA sequence capture and next-generation sequencing for the molecular diagnosis of genetic cardiomyopathies.J. Mol. Diagn.2014161324410.1016/j.jmoldx.2013.07.00824183960
     [Google Scholar]
  77. Personalized medicine: Identifying the appropriate patient through biomarkers in oncology.P&T2011367Suppl. 131021931468
     [Google Scholar]
  78. JainK.K. The Handbook of Biomarkers.Humana Press10.1007/978‑1‑60761‑685‑6
     [Google Scholar]
  79. HuanT. EskoT. PetersM.J. PillingL.C. SchrammK. SchurmannC. ChenB.H. LiuC. JoehanesR. JohnsonA.D. YaoC. YingS. CourchesneP. MilaniL. RaghavachariN. WangR. LiuP. ReinmaaE. DehghanA. HofmanA. UitterlindenA.G. HernandezD.G. BandinelliS. SingletonA. MelzerD. MetspaluA. CarstensenM. GrallertH. HerderC. MeitingerT. PetersA. RodenM. WaldenbergerM. DörrM. FelixS.B. ZellerT. VasanR. O’DonnellC.J. MunsonP.J. YangX. ProkischH. VölkerU. van MeursJ.B.J. FerrucciL. LevyD. A meta-analysis of gene expression signatures of blood pressure and hypertension.PLoS Genet.2015113e100503510.1371/journal.pgen.100503525785607
     [Google Scholar]
  80. TadaH FujinoN NomuraA NakanishiC HayashiK TakamuraM Personalized medicine for cardiovascular diseases.J Hum Genet2021661677410.1038/s10038‑020‑0818‑7
     [Google Scholar]
  81. DuncanK. Al-HaddadM. Arrhythmias.Springer202318519410.1007/978‑3‑031‑21991‑7_13
     [Google Scholar]
  82. Heart arrhythmia - Symptoms and causes2023Available from: https://www.mayoclinic.org/diseases-conditions/heart-arrhythmia/symptoms-causes/syc-20350668
  83. SD. TT. vC. Arrhythmia’s: Types, pathophysiology and therapy: A review.IRJP2019102233010.7897/2230‑8407.100236
     [Google Scholar]
  84. KarpawichP.P. Pathophysiology of Cardiac Arrhythmias: Arrhythmogenesis and types of Arrhythmias.Pathophysiology and Pharmacotherapy of Cardiovascular Disease.AdisCham20151003101410.1007/978‑3‑319‑15961‑4_47
     [Google Scholar]
  85. IwasakiY. NishidaK. KatoT. NattelS. Atrial fibrillation pathophysiology: Implications for management.Circulation2011124202264227410.1161/CIRCULATIONAHA.111.01989322083148
     [Google Scholar]
  86. WilliamsM.V. A classification of antiarrhythmic actions reassessed after a decade of new drugs.J. Clin. Pharmacol.198424412914710.1002/j.1552‑4604.1984.tb01822.x6144698
     [Google Scholar]
  87. ParidaS. ThangaswamyC. Cardiac tachyarrhythmias and anaesthesia: General principles and focus on atrial fibrillation.Indian J. Anaesth.201761971272010.4103/ija.IJA_383_1728970629
     [Google Scholar]
  88. RodenD.M. JohnsonJ.A. KimmelS.E. KraussR.M. MedinaM.W. ShuldinerA. WilkeR.A. Cardiovascular Pharmacogenomics.Circ. Res.2011109780782010.1161/CIRCRESAHA.110.23099521921273
     [Google Scholar]
  89. RodenD.M. Personalized medicine to treat arrhythmias.Curr. Opin. Pharmacol.201415616710.1016/j.coph.2013.11.01324721655
     [Google Scholar]
  90. DarbarD. Triggers for cardiac events in patients with type 2 long QT syndrome.Heart Rhythm20107121806180710.1016/j.hrthm.2010.09.07520887809
     [Google Scholar]
  91. VincentG.M. SchwartzP.J. DenjoyI. SwanH. BithellC. SpazzoliniC. CrottiL. PiippoK. LupoglazoffJ.M. VillainE. PrioriS.G. NapolitanoC. ZhangL. High efficacy of beta-blockers in long-QT syndrome type 1: Contribution of noncompliance and QT-prolonging drugs to the occurrence of beta-blocker treatment “failures”.Circulation2009119221522110.1161/CIRCULATIONAHA.108.77253319118258
     [Google Scholar]
  92. SchwartzP.J. AckermanM.J. GeorgeA.L.Jr WildeA.A.M. Impact of genetics on the clinical management of channelopathies.J. Am. Coll. Cardiol.201362316918010.1016/j.jacc.2013.04.04423684683
     [Google Scholar]
  93. WatanabeH. ChopraN. LaverD. HwangH.S. DaviesS.S. RoachD.E. DuffH.J. RodenD.M. WildeA.A.M. KnollmannB.C. Flecainide prevents catecholaminergic polymorphic ventricular tachycardia in mice and humans.Nat. Med.200915438038310.1038/nm.194219330009
     [Google Scholar]
  94. HusserD. AdamsV. PiorkowskiC. HindricksG. BollmannA. Chromosome 4q25 variants and atrial fibrillation recurrence after catheter ablation.J. Am. Coll. Cardiol.201055874775310.1016/j.jacc.2009.11.04120170812
     [Google Scholar]
  95. ShoemakerM.B. HusserD. RoselliC. Al JazairiM. ChrispinJ. KühneM. NeumannB. KnightS. SunH. MohantyS. ShafferC. ThériaultS. RinkeL.L. SilandJ.E. CrawfordD.M. UeberhamL. ZardkoohiO. BüttnerP. GeelhoedB. BlumS. AeschbacherS. SmithJ.D. Van WagonerD.R. FreudlingR. Müller-NurasyidM. MontgomeryJ. YonedaZ. WellsQ. IssaT. WeekeP. JacobsV. Van GelderI.C. HindricksG. BarnardJ. CalkinsH. DarbarD. MichaudG. KääbS. EllinorP. NataleA. ChungM. NazarianS. CutlerM.J. SinnerM.F. ConenD. RienstraM. BollmannA. RodenD.M. LubitzS. Genetic susceptibility for atrial fibrillation in patients undergoing atrial fibrillation ablation.Circ. Arrhythm. Electrophysiol.2020133e00767610.1161/CIRCEP.119.00767632078373
     [Google Scholar]
  96. BodyS.C. CollardC.D. ShernanS.K. FoxA.A. LiuK.Y. RitchieM.D. PerryT.E. MuehlschlegelJ.D. ArankiS. DonahueB.S. PretoriusM. EstradaJ.C. EllinorP.T. Newton-ChehC. SeidmanC.E. SeidmanJ.G. HermanD.S. LichtnerP. MeitingerT. PfeuferA. KääbS. BrownN.J. RodenD.M. DarbarD. Variation in the 4q25 chromosomal locus predicts atrial fibrillation after coronary artery bypass graft surgery.Circ. Cardiovasc. Genet.20092549950610.1161/CIRCGENETICS.109.84907520031626
     [Google Scholar]
  97. ParvezB. ChopraN. RowanS. VaglioJ.C. MuhammadR. RodenD.M. DarbarD. A common β1-adrenergic receptor polymorphism predicts favorable response to rate-control therapy in atrial fibrillation.J. Am. Coll. Cardiol.2012591495610.1016/j.jacc.2011.08.06122192668
     [Google Scholar]
  98. HuntD.J. JonesP.P. WangR. ChenW. BolstadJ. ChenK. ShimoniY. ChenS.R.W. K201 (JTV519) suppresses spontaneous Ca2+ release and [3H]ryanodine binding to RyR2 irrespective of FKBP12.6 association.Biochem. J.2007404343143810.1042/BJ2007013517313373
     [Google Scholar]
  99. LehnartS.E. TerrenoireC. ReikenS. WehrensX.H.T. SongL.S. TillmanE.J. MancarellaS. CoromilasJ. LedererW.J. KassR.S. MarksA.R. Stabilization of cardiac ryanodine receptor prevents intracellular calcium leak and arrhythmias.Proc. Natl. Acad. Sci. USA2006103207906791010.1073/pnas.060213310316672364
     [Google Scholar]
  100. ThygesenK. AlpertJ.S. WhiteH.D. JaffeA.S. AppleF.S. GalvaniM. KatusH.A. NewbyL.K. RavkildeJ. ChaitmanB. ClemmensenP.M. DellborgM. HodH. PorelaP. UnderwoodR. BaxJ.J. BellerG.A. BonowR. Van der WallE.E. BassandJ.P. WijnsW. FergusonT.B. StegP.G. UretskyB.F. WilliamsD.O. ArmstrongP.W. AntmanE.M. FoxK.A. HammC.W. OhmanE.M. SimoonsM.L. Poole-WilsonP.A. GurfinkelE.P. Lopez-SendonJ.L. PaisP. MendisS. ZhuJ.R. WallentinL.C. Fernández-AvilésF. FoxK.M. ParkhomenkoA.N. PrioriS.G. TenderaM. Voipio-PulkkiL.M. VahanianA. CammA.J. De CaterinaR. DeanV. DicksteinK. FilippatosG. Funck-BrentanoC. HellemansI. KristensenS.D. McGregorK. SechtemU. SilberS. TenderaM. WidimskyP. ZamoranoJ.L. MoraisJ. BrenerS. HarringtonR. MorrowD. LimM. Martinez-RiosM.A. SteinhublS. LevineG.N. GiblerW.B. GoffD. TubaroM. DudekD. Al-AttarN. Universal definition of myocardial infarction.Circulation2007116222634265310.1161/CIRCULATIONAHA.107.18739717951284
     [Google Scholar]
  101. ReimerK.A. JenningsR.B. TatumA.H. Pathobiology of acute myocardial ischemia: Metabolic, functional and ultrastructural studies.Am. J. Cardiol.1983522728110.1016/0002‑9149(83)90180‑76869259
     [Google Scholar]
  102. AppleF.S. SandovalY. JaffeA.S. Ordonez-LlanosJ. Cardiac troponin assays: Guide to understanding analytical characteristics and their impact on clinical care.Clin. Chem.2017631738110.1373/clinchem.2016.25510928062612
     [Google Scholar]
  103. CostaF.M. FerreiraJ. AguiarC. DoresH. FigueiraJ. MendesM. Impact of ESC/ACCF/AHA/WHF universal definition of myocardial infarction on mortality at 10 years.Eur. Heart J.201233202544255010.1093/eurheartj/ehs31122991454
     [Google Scholar]
  104. ChristiaP. FrangogiannisN.G. Pathophysiology of acute myocardial infarction.Adv Myocard Infarct Manag2013354610.2217/ebo.12.301
     [Google Scholar]
  105. SzmitkoP.E. WangC.H. WeiselR.D. JeffriesG.A. AndersonT.J. VermaS. Biomarkers of vascular disease linking inflammation to endothelial activation: Part II.Circulation2003108172041204810.1161/01.CIR.0000089093.75585.9814581382
     [Google Scholar]
  106. NiccoliG. CamiciP.G. Myocardial infarction with non-obstructive coronary arteries: What is the prognosis?Eur. Heart J. Suppl.202022Suppl. EE40E4510.1093/eurheartj/suaa05732523437
     [Google Scholar]
  107. Tamis-HollandJ.E. JneidH. ReynoldsH.R. AgewallS. BrilakisE.S. BrownT.M. LermanA. CushmanM. KumbhaniD.J. Arslanian-EngorenC. BolgerA.F. BeltrameJ.F. Contemporary diagnosis and management of patients with myocardial infarction in the absence of obstructive coronary artery disease: A scientific statement From the American Heart Association.Circulation201913918e891e90810.1161/CIR.000000000000067030913893
     [Google Scholar]
  108. HayesS.N. KimE.S.H. SawJ. AdlamD. Arslanian-EngorenC. EconomyK.E. GaneshS.K. GulatiR. LindsayM.E. MieresJ.H. NaderiS. ShahS. ThalerD.E. TweetM.S. WoodM.J. Spontaneous coronary artery dissection: Current state of the science: A scientific statement from the American Heart Association.Circulation201813719e523e55710.1161/CIR.000000000000056429472380
     [Google Scholar]
  109. LüscherT.F. PieperM. TenderaM. VrolixM. RutschW. van den BrandenF. GilR. BischoffK.O. HaudeM. FischerD. MeinertzT. MünzelT. A randomized placebo-controlled study on the effect of nifedipine on coronary endothelial function and plaque formation in patients with coronary artery disease: The ENCORE II study.Eur. Heart J.200930131590159710.1093/eurheartj/ehp15119474053
     [Google Scholar]
  110. GrootaertM.O.J. SchrijversD.M. Van SpaendonkH. BreynaertA. HermansN. Van HoofV.O. TakahashiN. VandenabeeleP. KimS.H. De MeyerG.R.Y. MartinetW. NecroX-7 reduces necrotic core formation in atherosclerotic plaques of Apoe knockout mice.Atherosclerosis201625216617410.1016/j.atherosclerosis.2016.06.04527425215
     [Google Scholar]
  111. SmitM. CoetzeeA.R. LochnerA. The pathophysiology of myocardial ischemia and perioperative myocardial infarction.J. Cardiothorac. Vasc. Anesth.20203492501251210.1053/j.jvca.2019.10.00531685419
     [Google Scholar]
  112. KumamotoM. NakashimaY. SueishiK. Intimal neovascularization in human coronary atherosclerosis: Its origin and pathophysiological significance.Hum. Pathol.199526445045610.1016/0046‑8177(95)90148‑57535741
     [Google Scholar]
  113. BurkeA.P. FarbA. MalcomG.T. LiangY. SmialekJ.E. VirmaniR. Plaque rupture and sudden death related to exertion in men with coronary artery disease.JAMA19992811092192610.1001/jama.281.10.92110078489
     [Google Scholar]
  114. BentzonJ.F. OtsukaF. VirmaniR. FalkE. Mechanisms of plaque formation and rupture.Circ. Res.2014114121852186610.1161/CIRCRESAHA.114.30272124902970
     [Google Scholar]
  115. Randomized trial of intravenous streptokinase, oral aspirin, both, or neither among 17,187 cases of suspected acute myocardial infarction: ISIS-2.J. Am. Coll. Cardiol.1988126Suppl. AA3A1310.1016/0735‑1097(88)92635‑62903874
     [Google Scholar]
  116. ApplebyP. BaigentC. CollinsR. FlatherM. ParishS. PetoR. Indications for fibrinolytic therapy in suspected acute myocardial infarction: collaborative overview of early mortality and major morbidity results from all randomised trials of more than 1000 patients.Lancet1994343889331132210.1016/S0140‑6736(94)91161‑47905143
     [Google Scholar]
  117. RoffiM. PatronoC. ColletJ.P. MuellerC. ValgimigliM. AndreottiF. BaxJ.J. BorgerM.A. BrotonsC. ChewD.P. GencerB. HasenfussG. KjeldsenK. LancellottiP. LandmesserU. MehilliJ. MukherjeeD. StoreyR.F. WindeckerS. 2015 ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation.Eur. Heart J.201637326731510.1093/eurheartj/ehv32026320110
     [Google Scholar]
  118. IbanezB. JamesS. AgewallS. AntunesM.J. Bucciarelli-DucciC. BuenoH. CaforioA.L.P. CreaF. GoudevenosJ.A. HalvorsenS. HindricksG. KastratiA. LenzenM.J. PrescottE. RoffiM. ValgimigliM. VarenhorstC. VranckxP. WidimskýP. ColletJ-P. KristensenS.D. AboyansV. BaumbachA. BugiardiniR. ComanI.M. DelgadoV. FitzsimonsD. GaemperliO. GershlickA.H. GielenS. HarjolaV-P. KatusH.A. KnuutiJ. KolhP. LeclercqC. LipG.Y.H. MoraisJ. NeskovicA.N. NeumannF-J. NiessnerA. PiepoliM.F. RichterD.J. ShlyakhtoE. SimpsonI.A. StegP.G. TerkelsenC.J. ThygesenK. WindeckerS. ZamoranoJ.L. ZeymerU. WindeckerS. AboyansV. AgewallS. BarbatoE. BuenoH. CocaA. ColletJ-P. ComanI.M. DeanV. DelgadoV. FitzsimonsD. GaemperliO. HindricksG. IungB. JüniP. KatusH.A. KnuutiJ. LancellottiP. LeclercqC. McDonaghT. PiepoliM.F. PonikowskiP. RichterD.J. RoffiM. ShlyakhtoE. SimpsonI.A. ZamoranoJ.L. ChettibiM. HayrapetyanH.G. MetzlerB. IbrahimovF. SujayevaV. BeauloyeC. Dizdarevic-HudicL. KaramfiloffK. SkoricB. AntoniadesL. TousekP. TerkelsenP.C.J. ShaheenS.M. MarandiT. NiemeläM. KedevS. GilardM. AladashviliA. ElsaesserA. KanakakisI.G. MerkelyB. GudnasonT. IakobishviliZ. BologneseL. BerkinbayevS. BajraktariG. BeishenkulovM. ZakeI. LaminH.B. GustieneO. PereiraB. XuerebR.G. ZtotS. JuliebøV. LegutkoJ. TimóteoA.T. Tatu-ChiţoiuG. YakovlevA. BertelliL. NedeljkovicM. StudenčanM. BuncM. García de CastroA.M. PeturssonP. JegerR. MouraliM.S. YildirirA. ParkhomenkoA. GaleC.P. 2017 ESC Guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation.Eur. Heart J.201839211917710.1093/eurheartj/ehx39328886621
     [Google Scholar]
  119. ScottR.A. FreitagD.F. LiL. ChuA.Y. SurendranP. YoungR. GrarupN. StancákováA. ChenY. VargaT.V. YaghootkarH. LuanJ. ZhaoJ.H. WillemsS.M. WesselJ. WangS. MaruthurN. MichailidouK. PirieA. van der LeeS.J. GillsonC. Al OlamaA.A. AmouyelP. ArriolaL. ArveilerD. Aviles-OlmosI. BalkauB. BarricarteA. BarrosoI. GarciaS.B. BisJ.C. BlankenbergS. BoehnkeM. BoeingH. BoerwinkleE. BoreckiI.B. Bork-JensenJ. BowdenS. CaldasC. CaslakeM. CupplesL.A. CruchagaC. CzajkowskiJ. den HoedM. DunnJ.A. EarlH.M. EhretG.B. FerranniniE. FerrieresJ. FoltynieT. FordI. ForouhiN.G. GianfagnaF. GonzalezC. GrioniS. HillerL. JanssonJ.H. JørgensenM.E. JukemaJ.W. KaaksR. KeeF. KerrisonN.D. KeyT.J. KonttoJ. Kote-JaraiZ. KrajaA.T. KuulasmaaK. KuusistoJ. LinnebergA. LiuC. MarenneG. MohlkeK.L. MorrisA.P. MuirK. Müller-NurasyidM. MunroeP.B. NavarroC. NielsenS.F. NilssonP.M. NordestgaardB.G. PackardC.J. PalliD. PanicoS. PelosoG.M. PerolaM. PetersA. PooleC.J. QuirósJ.R. RolandssonO. SacerdoteC. SalomaaV. SánchezM.J. SattarN. SharpS.J. SimsR. SlimaniN. SmithJ.A. ThompsonD.J. TrompetS. TuminoR. van der AD.L. van der SchouwY.T. VirtamoJ. WalkerM. WalterK. AbrahamJ.E. AmundadottirL.T. AponteJ.L. ButterworthA.S. DupuisJ. EastonD.F. EelesR.A. ErdmannJ. FranksP.W. FraylingT.M. HansenT. HowsonJ.M.M. JørgensenT. KoonerJ. LaaksoM. LangenbergC. McCarthyM.I. PankowJ.S. PedersenO. RiboliE. RotterJ.I. SaleheenD. SamaniN.J. SchunkertH. VollenweiderP. O’RahillyS. DeloukasP. DaneshJ. GoodarziM.O. KathiresanS. MeigsJ.B. EhmM.G. WarehamN.J. WaterworthD.M. A genomic approach to therapeutic target validation identifies a glucose-lowering GLP1R variant protective for coronary heart disease.Sci. Transl. Med.20168341341ra7610.1126/scitranslmed.aad374427252175
     [Google Scholar]
  120. ClaassensD.M.F. VosG.J.A. BergmeijerT.O. HermanidesR.S. van ’t HofA.W.J. van der HarstP. BarbatoE. MoriscoC. Tjon Joe GinR.M. AsselbergsF.W. MosterdA. HerrmanJ.P.R. DewildeW.J.M. JanssenP.W.A. KelderJ.C. PostmaM.J. de BoerA. BoersmaC. DeneerV.H.M. ten BergJ.M. A genotype-guided strategy for oral P2Y 12 inhibitors in primary PCI.N. Engl. J. Med.2019381171621163110.1056/NEJMoa190709631479209
     [Google Scholar]
  121. PereiraN.L. FarkouhM.E. SoD. LennonR. GellerN. MathewV. BellM. BaeJ.H. JeongM.H. ChavezI. GordonP. AbbottJ.D. CaginC. BaudhuinL. FuY.P. GoodmanS.G. HasanA. IturriagaE. LermanA. SidhuM. TanguayJ.F. WangL. WeinshilboumR. WelshR. RosenbergY. BaileyK. RihalC. Effect of genotype-guided oral P2Y12 inhibitor selection vs conventional clopidogrel therapy on ischemic outcomes after percutaneous coronary intervention.JAMA2020324876177110.1001/jama.2020.1244332840598
     [Google Scholar]
  122. BhattacharyaS. GrangerC.B. CraigD. HaynesC. BainJ. StevensR.D. HauserE.R. NewgardC.B. KrausW.E. NewbyL.K. ShahS.H. Validation of the association between a branched chain amino acid metabolite profile and extremes of coronary artery disease in patients referred for cardiac catheterization.Atherosclerosis2014232119119610.1016/j.atherosclerosis.2013.10.03624401236
     [Google Scholar]
  123. ShahR.V. TruongQ.A. GagginH.K. PfannkucheJ. HartmannO. JanuzziJ.L.Jr Mid-regional pro-atrial natriuretic peptide and pro-adrenomedullin testing for the diagnostic and prognostic evaluation of patients with acute dyspnoea.Eur. Heart J.201233172197220510.1093/eurheartj/ehs13622645194
     [Google Scholar]
  124. TanzilliG. ArriviA. PlacanicaA. ViceconteN. CammisottoV. NocellaC. BarillàF. TorromeoC. PucciG. AcconciaM.C. GranatelliA. BasiliS. DominiciM. GaudioC. CarnevaleR. MangieriE. Glutathione infusion before and 3 days after primary angioplasty blunts ongoing NOX2-mediated inflammatory response.J. Am. Heart Assoc.20211018e02056010.1161/JAHA.120.02056034533039
     [Google Scholar]
  125. MaY. YuanY. AiliZ. MaitusongM. LiH. NijiatiM. Proteomics analysis of coronary blood microparticles in patients with acute myocardial infarction.Cardiol. J.202330228629610.5603/CJ.a2022.008136036671
     [Google Scholar]
  126. Valdes-MarquezE. ClarkeR. HillM. WatkinsH. HopewellJ.C. Proteomic profiling identifies novel independent relationships between inflammatory proteins and myocardial infarction.Eur. J. Prev. Cardiol.202330758359110.1093/eurjpc/zwad02036702559
     [Google Scholar]
  127. PanY. WangL. XieY. TanY. ChangC. QiuX. LiX. Characterization of differentially expressed plasma proteins in patients with acute myocardial infarction.J. Proteomics202022710392310.1016/j.jprot.2020.10392332736138
     [Google Scholar]
  128. XieY. ZhangH. HuangT. Quantitative proteomics reveal three potential biomarkers for risk assessment of acute myocardial infarction.Bioengineered20221334939495010.1080/21655979.2022.203736535156527
     [Google Scholar]
  129. ZhanC. TangT. WuE. ZhangY. HeM. WuR. BiC. WangJ. ZhangY. ShenB. From multi-omics approaches to personalized medicine in myocardial infarction.Front. Cardiovasc. Med.202310125034010.3389/fcvm.2023.125034037965091
     [Google Scholar]
  130. WheltonP.K. CareyR.M. AronowW.S. CaseyD.E.Jr CollinsK.J. Dennison HimmelfarbC. DePalmaS.M. GiddingS. JamersonK.A. JonesD.W. MacLaughlinE.J. MuntnerP. OvbiageleB. SmithS.C.Jr SpencerC.C. StaffordR.S. TalerS.J. ThomasR.J. WilliamsK.A.Sr WilliamsonJ.D. WrightJ.T.Jr 2017 ACC/AHA/AAPA/ABC/ACPM/AGS/APhA/ ASH/ASPC/NMA/PCNA guideline for the prevention, detection, evaluation, and management of high blood pressure in adults a report of the American College of Cardiology/American Heart Association Task Force on Clinical practice guidelines.Hypertension2018716e13e11510.1161/HYP.0000000000000065/SUPPL_FILE/DATA_SUPPLEMENT29133356
     [Google Scholar]
  131. AronowW.S. FlegJ.L. PepineC.J. ArtinianN.T. BakrisG. BrownA.S. FerdinandK.C. ForcieaM.A. FrishmanW.H. JaigobinC. KostisJ.B. ManciaG. OparilS. OrtizE. ReisinE. RichM.W. SchockenD.D. WeberM.A. WesleyD.J. HarringtonR.A. ACCF/AHA 2011 expert consensus document on hypertension in the elderly.Circulation2011123212434250610.1161/CIR.0b013e31821daaf621518977
     [Google Scholar]
  132. HallJ.E. do CarmoJ.M. da SilvaA.A. WangZ. HallM.E. Obesity-induced hypertension.Circ. Res.20151166991100610.1161/CIRCRESAHA.116.30569725767285
     [Google Scholar]
  133. PadmanabhanS. CaulfieldM. DominiczakA.F. Genetic and molecular aspects of hypertension.Circ. Res.2015116693795910.1161/CIRCRESAHA.116.30364725767282
     [Google Scholar]
  134. UngerT. BorghiC. CharcharF. KhanN.A. PoulterN.R. PrabhakaranD. RamirezA. SchlaichM. StergiouG.S. TomaszewskiM. WainfordR.D. WilliamsB. SchutteA.E. 2020 international society of hypertension global hypertension practice guidelines.Hypertension20207561334135710.1161/HYPERTENSIONAHA.120.1502632370572
     [Google Scholar]
  135. KowalskiS. GoniewiczK. MoskalA. Al-WathinaniA.M. GoniewiczM. Symptoms in hypertensive patients presented to the emergency medical service: A comprehensive retrospective analysis in clinical settings.J Clin Med20231217549510.3390/jcm12175495
     [Google Scholar]
  136. BeeversG. LipG.Y.H. O’BrienE. ABC of hypertension: The pathophysiology of hypertension.BMJ2001322729191291610.1136/bmj.322.7291.91211302910
     [Google Scholar]
  137. te RietL. van EschJ.H.M. RoksA.J.M. van den MeirackerA.H. DanserA.H.J. Hypertension.Circ. Res.2015116696097510.1161/CIRCRESAHA.116.30358725767283
     [Google Scholar]
  138. MorrisR.C.Jr SchmidlinO. SebastianA. TanakaM. KurtzT.W. RC M Vasodysfunction that involves renal vasodysfunction, not abnormally increased renal retention of sodium, accounts for the initiation of salt-induced hypertension.Circulation2016133988189310.1161/CIRCULATIONAHA.115.017923
     [Google Scholar]
  139. FurbergC.D. WrightJ.T. DavisB.R. CutlerJ.A. AldermanM. BlackH. Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic: The antihypertensive and lipid-lowering treatment to prevent heart attack trial (ALLHAT).JAMA2002288232981299710.1001/jama.288.23.298112479763
     [Google Scholar]
  140. CareyR.M. MoranA.E. WheltonP.K. Treatment of Hypertension.JAMA2022328181849186110.1001/jama.2022.1959036346411
     [Google Scholar]
  141. TurnerST SchwartzGL BoerwinkleE Personalized medicine for high blood pressure.Hypertension20075011510.1161/HYPERTENSIONAHA.107.087049
     [Google Scholar]
  142. McDonoughC.W. MagvanjavO. SáA.C.C. El RoubyN.M. DaveC. DeitchmanA.N. Kawaguchi-SuzukiM. MeiW. ShenY. SinghR.S.P. SolaymanM. BaileyK.R. BoerwinkleE. ChapmanA.B. GumsJ.G. WebbA. SchererS.E. SadeeW. TurnerS.T. Cooper-DeHoffR.M. GongY. JohnsonJ.A. Genetic Variants Influencing Plasma Renin Activity in Hypertensive Patients From the PEAR Study (Pharmacogenomic Evaluation of Antihypertensive Responses).Circ. Genom. Precis. Med.2018114e00185410.1161/CIRCGEN.117.00185429650764
     [Google Scholar]
  143. SáA.C.C. WebbA. GongY. McDonoughC.W. ShahinM.H. DattaS. LangaeeT.Y. TurnerS.T. BeitelsheesA.L. ChapmanA.B. BoerwinkleE. GumsJ.G. SchererS.E. Cooper-DeHoffR.M. SadeeW. JohnsonJ.A. Blood pressure signature genes and blood pressure response to thiazide diuretics: Results from the PEAR and PEAR-2 studies.BMC Med. Genomics20181115510.1186/s12920‑018‑0370‑x29925376
     [Google Scholar]
  144. LaraghJ.H. LetcherR.L. PickeringT.G. Renin profiling for diagnosis and treatment of hypertension.JAMA1979241215115610.1001/jama.1979.0329028003102231492
     [Google Scholar]
  145. RydbergD.M. MejyrS. LoikasD. Schenck-GustafssonK. von EulerM. MalmströmR.E. Sex differences in spontaneous reports on adverse drug events for common antihypertensive drugs.Eur. J. Clin. Pharmacol.20187491165117310.1007/s00228‑018‑2480‑y29804162
     [Google Scholar]
  146. BrewsterL.M. SeedatY.K. Why do hypertensive patients of African ancestry respond better to calciumblockers and diuretics than to ACE inhibitors and β-adrenergic blockers? Asystematic review.BMC Med.201311114110.1186/1741‑7015‑11‑14123721258
     [Google Scholar]
  147. Cooper-DeHoffR.M. JohnsonJ.A. Hypertension pharmacogenomics: in search of personalized treatment approaches.Nat. Rev. Nephrol.201612211012210.1038/nrneph.2015.17626592190
     [Google Scholar]
  148. NatarajanP. YoungR. StitzielN.O. PadmanabhanS. BaberU. MehranR. SartoriS. FusterV. ReillyD.F. ButterworthA. RaderD.J. FordI. SattarN. KathiresanS. Polygenic risk score identifies subgroup with higher burden of atherosclerosis and greater relative benefit from statin therapy in the primary prevention setting.Circulation2017135222091210110.1161/CIRCULATIONAHA.116.02443628223407
     [Google Scholar]
  149. KnowlesJ.W. AshleyE.A. Cardiovascular disease: The rise of the genetic risk score.PLoS Med.2018153e100254610.1371/journal.pmed.100254629601582
     [Google Scholar]
  150. AraujoA. JuliousS. SennS. Understanding variation in sets of N-of-1 trials.PLoS One20161112e016716710.1371/journal.pone.016716727907056
     [Google Scholar]
  151. Ischemic Heart Disease.National Academies PressUS2010
     [Google Scholar]
  152. OpieL.H. Angina pectoris: The evolution of concepts.J. Cardiovasc. Pharmacol. Ther.200491_supplSuppl. 1S3S910.1177/10742484040090010215378128
     [Google Scholar]
  153. BallaC. PavasiniR. FerrariR. Treatment of Angina: Where are we?Cardiology20181401526710.1159/00048793629874661
     [Google Scholar]
  154. RousanT.A. ThadaniU. Stable Angina medical therapy management guidelines: A critical review of guidelines from the european society of cardiology and national institute for health and care excellence.Eur. Cardiol.2019141182210.15420/ecr.2018.26.131131033
     [Google Scholar]
  155. WeeY. BurnsK. BettN. Medical management of chronic stable angina.Aust. Prescr.201538413113610.18773/austprescr.2015.04226648642
     [Google Scholar]
  156. SilvaF.M.F. PesaroA.E.P. FrankenM. WajngartenM. Acute management of unstable angina and non-ST segment elevation myocardial infarction.Einstein201513345446110.1590/S1679‑45082015RW3172
     [Google Scholar]
  157. YusufS. ZhaoF. MehtaS.R. ChrolaviciusS. TognoniG. FoxK.K. Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation.N. Engl. J. Med.2001345749450210.1056/NEJMoa01074611519503
     [Google Scholar]
  158. MegaJ.L. StitzielN.O. SmithJ.G. ChasmanD.I. CaulfieldM.J. DevlinJ.J. NordioF. HydeC.L. CannonC.P. SacksF.M. PoulterN.R. SeverP.S. RidkerP.M. BraunwaldE. MelanderO. KathiresanS. SabatineM.S. Genetic risk, coronary heart disease events, and the clinical benefit of statin therapy: An analysis of primary and secondary prevention trials.Lancet201538599842264227110.1016/S0140‑6736(14)61730‑X25748612
     [Google Scholar]
  159. IakoubovaO.A. TongC.H. RowlandC.M. KirchgessnerT.G. YoungB.A. ArellanoA.R. ShiffmanD. SabatineM.S. CamposH. PackardC.J. PfefferM.A. WhiteT.J. BraunwaldE. ShepherdJ. DevlinJ.J. SacksF.M. Association of the Trp719Arg polymorphism in kinesin-like protein 6 with myocardial infarction and coronary heart disease in 2 prospective trials: The CARE and WOSCOPS trials.J. Am. Coll. Cardiol.200851443544310.1016/j.jacc.2007.05.05718222353
     [Google Scholar]
  160. CarboneF. MontecuccoF. MachF. Update on evidence for treatment with ranolazine in stable angina.Swiss Med. Wkly.2013143w13874w1387410.4414/smw.2013.1387424163124
     [Google Scholar]
  161. IqbalJ. SerruysP.W. Revascularization strategies for patients with stable coronary artery disease.J. Intern. Med.2014276433635110.1111/joim.1224324690076
     [Google Scholar]
  162. GajareS.R. DeshmukhA.S. ShindeC.K. Personalized medicine: A review.Int. J. Pharm. Sci. Rev. Res.202169110.47583/ijpsrr.2021.v69i01.023
     [Google Scholar]
  163. Stefanicka-WojtasD. KurpasD. Personalised medicine—implementation to the healthcare system in Europe (focus group discussions).J. Pers. Med.202313338010.3390/jpm1303038036983562
     [Google Scholar]
  164. LermanA. ZeiherA.M. Endothelial Function.Circulation2005111336336810.1161/01.CIR.0000153339.27064.1415668353
     [Google Scholar]
  165. RubinshteinR. YangE.H. RihalC.S. PrasadA. LennonR.J. BestP.J. LermanL.O. LermanA. Coronary microcirculatory vasodilator function in relation to risk factors among patients without obstructive coronary disease and low to intermediate Framingham score.Eur. Heart J.201031893694210.1093/eurheartj/ehp45919897496
     [Google Scholar]
  166. RubinshteinR. KuvinJ.T. SofflerM. LennonR.J. LaviS. NelsonR.E. PumperG.M. LermanL.O. LermanA. Assessment of endothelial function by non-invasive peripheral arterial tonometry predicts late cardiovascular adverse events.Eur. Heart J.20103191142114810.1093/eurheartj/ehq01020181680
     [Google Scholar]
  167. HamburgN.M. KeyesM.J. LarsonM.G. VasanR.S. SchnabelR. PrydeM.M. MitchellG.F. SheffyJ. VitaJ.A. BenjaminE.J. Cross-sectional relations of digital vascular function to cardiovascular risk factors in the Framingham Heart Study.Circulation2008117192467247410.1161/CIRCULATIONAHA.107.74857418458169
     [Google Scholar]
  168. McCreaC.E. Skulas-RayA.C. ChowM. WestS.G. Test–retest reliability of pulse amplitude tonometry measures of vascular endothelial function: Implications for clinical trial design.Vasc. Med.2012171293610.1177/1358863X1143318822363016
     [Google Scholar]
  169. SplawskiI. TimothyK.W. TateyamaM. ClancyC.E. MalhotraA. BeggsA.H. CappuccioF.P. SagnellaG.A. KassR.S. KeatingM.T. Variant of SCN5A sodium channel implicated in risk of cardiac arrhythmia.Science200229755851333133610.1126/science.107356912193783
     [Google Scholar]
  170. ErdmannJ. Linsel-NitschkeP. SchunkertH. Genetic causes of myocardial infarction: New insights from genome-wide association studies.Dtsch. Arztebl. Int.20101074069469910.3238/arztebl.2010.069421031128
     [Google Scholar]
  171. DugasC.M. SchusslerJ.M. Advanced technology in interventional cardiology: A roadmap for the future of precision coronary interventions.Trends Cardiovasc. Med.201626546647310.1016/j.tcm.2016.02.00327020905
     [Google Scholar]
  172. KramerB.S. CroswellJ.M. Cancer screening: The clash of science and intuition.Annu. Rev. Med.200960112513710.1146/annurev.med.60.101107.13480218803476
     [Google Scholar]
  173. WeinshilboumR. Inheritance and drug response.N. Engl. J. Med.2003348652953710.1056/NEJMra02002112571261
     [Google Scholar]
  174. HamburgM.A. CollinsF.S. The path to personalized medicine.N. Engl. J. Med.2010363430130410.1056/NEJMp100630420551152
     [Google Scholar]
  175. HarrisonR. Harrison’S Principles of Internal Medicine.McGraw-Hill Education17th ed2008
     [Google Scholar]
  176. JohnsonJ.A. LimaJ.J. Drug receptor/effector polymorphisms and pharmacogenetics.Pharmacogenetics200313952553410.1097/00008571‑200309000‑0000112972951
     [Google Scholar]
  177. CaliffR.M. GinsburgG.S. Organizational improvements to enhance modern clinical epidemiology.JAMA2008300192300230210.1001/jama.2008.63819017917
     [Google Scholar]
  178. AbrahamsE. SilverM. The case for personalized medicine.J. Diabetes Sci. Technol.20093468068410.1177/19322968090030041120144313
     [Google Scholar]
  179. World Health Organization. Cardiovascular diseases.Cardiovascular diseases.https://www.who.int/health-topics/cardiovascular-diseases#tab=tab_1
/content/journals/chddt/10.2174/011871529X361429250215190129
Loading
Treating Cardiovascular Disorders with Personalized Medicine
Cardiovasc Hematol Disord Drug Targets 25, 98 (2025); https://doi.org/10.2174/011871529X361429250215190129
/content/journals/chddt/10.2174/011871529X361429250215190129
/content/journals/chddt/10.2174/011871529X361429250215190129
Loading

Data & Media loading...


  • Article Type:     Review Article
Keyword(s): 3-D printing; bioinformatics; Cardiovascular disorders; genomics; personalized cardiology; polypill; proteomics

Most Cited Most Cited RSS feed

This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error
Please enter a valid_number test